Table 1 Patient demographics and characteristics
Nivolumab | Nivolumab plus relatlimab | |
|---|---|---|
n (female, male) | 30 (15, 15) | 30 (13, 17) |
Age in years, median (range) | 64 (43–77) | 67 (43–81) |
ECOG PS (0, 1) | 28, 2 | 28, 2 |
Histology | ||
Adenocarcinoma | 13 | 15 |
Squamous cell carcinoma | 10 | 9 |
Adenosquamous carcinoma | 2 | 2 |
Other | 5 | 4 |
Clinical stage (UICC eighth edition) | ||
IB | 8 | 10 |
IIA | 5 | 1 |
IIB | 13 | 16 |
IIIA | 4 | 3 |
PD-L1 status (TPS) | ||
<1% | 6 | 8 |
1–49% | 14 | 15 |
≥50% | 10 | 7 |
Smoking status | ||
Current | 5 | 16 |
Former | 22 | 13 |
Nonsmoker | 3 | 1 |
Occupational exposure | ||
Yes | 2 | 3 |
No | 27 | 26 |
Unknown | 1 | 1 |
